[Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].
A 69-year-old-man undergoing hemodialysis for 8 years developed metastatic urothelial carcinoma and received combination chemotherapy with paclitaxel and carboplatin. Paclitaxel 175 mg/m2 was given as a 3-hour intravenous infusion, and carboplatin was dosed to the area under the plasma concentration-time curve (AUC) of 5 mg.min/ml calculated according to the Calvert formula as a 30-minute intravenous infusion immediately after paclitaxel. Hemodialysis was started 1 hour after carboplatin, then their pharmacokinetics was determined in the patient. The AUC of paclitaxel and carboplatin were 15.2 and 64.56 micrograms.h/ml, respectively. The metastatic tumor size was reduced by more than 20% after 3 courses of this chemotherapy. Grade 3 neutropenia and grade 1 thrombopenia were observed. This is the first report that the combination of paclitaxel and carboplatin is feasible in a patient with metastatic urothelial carcinoma undergoing hemodialysis, with low toxicity and safety.
Furuya
Yasuhisa
Y
Dept. of Urology, Faculty of Medicine, University of Yamanashi.
Takihana
Yoshio
Y
Araki
Isao
I
Tanabe
Nobuaki
N
Takeda
Masayuki
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary*; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D007680:Kidney Neoplasms / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics; D006435:Renal Dialysis; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
D016190:Carboplatin; D017239:Paclitaxel